Explore thymosin alpha-1 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized thymosin alpha-1 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid immune-modulating peptide most often sourced for immune-support and antiviral research. Sold abroad as the approved drug Zadaxin for chronic hepatitis B and C, it holds FDA orphan-drug designation but no full U.S. approval. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
Thymosin alpha-1 signals through Toll-like receptors (particularly TLR-2 and TLR-9) on dendritic cells and monocytes, biasing dendritic-cell maturation toward Th1 polarization, increasing IL-2 and IFN-γ production, and enhancing CD8 cytotoxic-T-cell and natural-killer-cell activity. It does not act as a thymic-hormone replacement; rather, it acts as a pattern-recognition-receptor-mediated immune modulator.[2]
Randomized trials and large registry data support efficacy in chronic hepatitis B (Andreone et al.), chronic hepatitis C combination regimens, and post-vaccine immune response in elderly subjects.[3] During the COVID-19 pandemic, several Chinese cohort studies reported reduced mortality in severe COVID-19 patients treated with thymosin alpha-1 as an adjunct — these were observational and not confirmed in randomized Western trials.[4]
Approved as Zadaxin in 35+ countries for chronic hepatitis B and C. FDA orphan-drug designation for hepatitis B, malignant melanoma, and DiGeorge syndrome, but no full FDA approval. Research-grade material is not for human use.
Thymosin Alpha-1 has a reported half-life of ~2 hours. The pharmacokinetic reference models an interval of twice weekly; this is not a measured community cadence or a dosing recommendation. A short half-life means each dose clears well before the next on a twice-weekly schedule, so there is no plasma buildup; the immune-modulating effect outlasts the blood level. Pharmacokinetic source: Clinical PK for thymalfasin (Zadaxin). It is catalogued under Recovery Peptides on WPA.
356 Thymosin Alpha-1 reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
Thymosin Alpha-1 (Tα1) is a 28-amino acid acetylated peptide originally isolated from the bovine thymic extract thymosin fraction 5 by Allan Goldstein's laboratory at the Albert Einstein College of Medicine in 1972, and characterized through subsequent decades of work as the most clinically advanced single peptide in the thymic-extract family. Tα1 acts upstream of T-cell maturation through Toll-like receptor 9 (TLR9) and TLR2 signaling on dendritic cells, driving Th1-skewed cytokine release and CD4+/CD8+ T-cell expansion — a mechanism distinct from the Khavinson short-peptide bioregulators (Vilon, Thymalin, Testagen) that occupy adjacent pages on this site, and distinct again from the Bach/Dardenne thymulin nonapeptide. The molecule's regulatory and clinical record is the most developed of any thymic peptide on this site, anchored on the SciClone Pharmaceuticals "ZADAXIN" program: Tα1 carries FDA Orphan Drug Designation in the United States (granted for chronic hepatitis B, hepatocellular carcinoma, and DiGeorge anomaly indications) without a full FDA marketing approval, and is EMA-approved through national authorization procedures in multiple European member states (most prominently Italy, where it is marketed for chronic hepatitis B and C), with broader marketing approval across 35+ countries globally including China, Russia, Argentina, and Mexico for chronic hepatitis B and C as monotherapy or in combination with interferon and antivirals. It has also been studied as adjuvant therapy in non-small-cell lung cancer and melanoma (the Italian Phase 3 adjuvant programs) and in severe sepsis (the Phase 3 ETASS / SciClone "TASS" sepsis program in China, 2008-2013) with positive but contested mortality signals.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.